Rubber-Series Patch Tests in 2,870 of 29,522 Patients
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: What did an additional rubber series find beyond baseline screening?
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 29,522 European patch-test patients, including 2,870 tested with both a baseline series and an additional rubber series. |
| Design | Retrospective ESSCA multicenter analysis of baseline and supplemental rubber-allergen testing. |
| Comparator | Baseline-series screening results were compared with additional rubber-series results within the 2,870 eligible patients and with baseline results in the broader cohort. |
| Timepoint | 2013-2014. |
| Key result | Among the 2,870 dual-tested patients, 8.8% reacted to a baseline rubber-screening allergen, 12.3% to an additional rubber-series allergen and 6.4% to both. |
| Funding/conflict context | The indexed abstract does not report funding or conflicts and does not evaluate a moisturizer. |
What was actually measured?
Among the 2,870 dual-tested patients, 8.8% reacted to a baseline rubber-screening allergen, 12.3% to an additional rubber-series allergen and 6.4% to both.
Because additional testing was clinically selected, its yield supports diagnostic breadth but cannot be treated as prevalence in all workers or glove users.
The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.
What the result does not prove
Selected referral patients, nonuniform departmental rubber series and confounding by indication limit direct comparison and generalization.
Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.
A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.
Exposure detail matters more than the job label
Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.
A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.
Questions worth recording
- Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
- Where did the change begin, and did it improve on days away or after a process or PPE change?
- How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
- Were labels, ingredient information and safety-data sheets reviewed with occupational health?
- Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?
Prevention comes before cosmetic care
Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.
Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.
Primary research and guidance
- Primary research record: PubMed PMID 27402420
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis
- American Academy of Dermatology: eczema skin care
Where Dr. Arsy #003 fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Objective Skin-Barrier Measures in 185 Physicians, Dentists and Controls
- Hand-to-Forearm Barrier Measures in 148 Physicians and Dentists
- Recognized Occupational Dermatitis in 381 Danish Hairdressers
- Workplace-Irritant Assessment in 316 Suspected Hand-Dermatitis Patients
Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.